LifeMine Therapeutics is a clinical-stage biopharmaceutical company pioneering "Top-Down Drug Discovery™" by leveraging evolutionary insights from fungi to unearth next-generation precision medicines. Their data-immersive and technologically expansive discovery engine aims to bring sophisticated medicines to patients in urgent need of breakthrough disease intervention. The company's lead clinical-stage program, LIFE-001, is a novel calcineurin activation inhibitor being developed for the prevention of organ transplant rejection.